Kenvue Inc. (NYSE:KVUE) Shares Bought by Yousif Capital Management LLC

Yousif Capital Management LLC raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 26.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 342,684 shares of the company’s stock after buying an additional 72,504 shares during the quarter. Yousif Capital Management LLC’s holdings in Kenvue were worth $7,378,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. purchased a new stake in shares of Kenvue in the third quarter worth approximately $2,944,816,000. FMR LLC lifted its position in shares of Kenvue by 572.1% in the third quarter. FMR LLC now owns 89,182,980 shares of the company’s stock worth $1,790,794,000 after purchasing an additional 75,913,107 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Kenvue by 576.1% in the third quarter. Wellington Management Group LLP now owns 71,686,830 shares of the company’s stock worth $1,439,472,000 after purchasing an additional 61,084,123 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Kenvue by 227.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 61,091,189 shares of the company’s stock worth $1,226,711,000 after purchasing an additional 42,449,470 shares in the last quarter. Finally, Morgan Stanley increased its holdings in Kenvue by 4,057.4% in the third quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock worth $625,745,000 after buying an additional 30,413,040 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective on the stock. JPMorgan Chase & Co. dropped their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. William Blair assumed coverage on Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. Sanford C. Bernstein started coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective on the stock. Finally, Royal Bank of Canada lowered their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $24.85.

Kenvue Trading Down 0.2 %

Shares of Kenvue stock opened at $19.10 on Thursday. The company’s fifty day simple moving average is $19.84 and its 200-day simple moving average is $20.15. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. Kenvue Inc. has a 1 year low of $17.82 and a 1 year high of $27.80.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.03. The business had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The company’s revenue was down 2.7% on a year-over-year basis. As a group, sell-side analysts expect that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.